FDA Considering Naming Convention For Biosimilar And Interchangeable Products

FDA is currently considering the appropriate naming convention for biosimilar and interchangeable products, and the agency will take into consideration comments submitted to dockets on proposed biosimilar products in finalizing biosimilar guidances and developing future policies, an agency spokesperson told Inside Health Policy . The agency recently updated the drug center's guidance agenda for this year by adding a draft guidance on generic opioid drug evaluation, while continuing to list four upcoming draft guidances for biosimilars: Biosimilars: Additional Questions and...